Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Acute Myeloid Leukemia Clear all
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine phosphate, melphalan, allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
7 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:51 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Kansas City, Missouri • Rochester, New York • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
laromustine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Filgrastim, Cyclosporine, Decitabine, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
bortezomib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo
Drug
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Other
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Panobinostat (LBH589), 5-Azacytidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
8
States / cities
Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced May 22, 2026, 3:51 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
NiCord®
Drug
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
12 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Maywood, Illinois • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult T Acute Lymphoblastic Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced May 22, 2026, 3:51 AM EDT
Terminated Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Emerfetamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Birmingham, Alabama • Duarte, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced May 22, 2026, 3:51 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
97
States / cities
Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Ara-C, BL-8040
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
cyclophosphamide, fludarabine phosphate, tacrolimus, mycophenolate mofetil, polymerase chain reaction, fluorescence in situ hybridization, polymorphism analysis, gene expression analysis, total-body irradiation, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
Drug · Genetic · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
Interventions
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose
Drug
Lead sponsor
BlueSphere Bio, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced May 22, 2026, 3:51 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
7
States / cities
Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 22, 2026, 3:51 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
14 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced May 22, 2026, 3:51 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
Interventions
SOC+BSB-2002
Drug
Lead sponsor
BlueSphere Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 3:51 AM EDT